The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Zanzalintinib (XL092) alone or in combination with atezolizumab in patients (pts) with refractory metastatic colorectal cancer (mCRC): Results from an expansion cohort of the phase 1 STELLAR-001 study.
 
Elisa Fontana
Employment - HCA/Sarah Cannon
Leadership - European Organisation for Research and Treatment of Cancer (EORTC)
Consulting or Advisory Role - Astellas Pharma; Bicycle Therapeutics; BMS; Pfizer
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carrick Therapeutics (Inst); CASI Pharmaceuticals (Inst); Clovis Oncology (Inst); Crescendo Biologics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Ellipses Pharma (Inst); Exelixis (Inst); Fore Biotherapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); HUTCHMED (Inst); Ignyta/Genentech/Roche (Inst); Immunocore (Inst); Immunomedics (Inst); Incyte (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Kronos Bio (Inst); Lilly (Inst); Lupin Pharmaceuticals (Inst); Macrogenics (Inst); Menarini (Inst); Merck KGaA (Inst); Mereo Biopharma (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Nerviano Medical Sciences (Inst); Nurix (Inst); Oxford VacMedix (Inst); Pfizer (Inst); Plexxikon (Inst); PMV Pharma (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Roche (Inst); Sapience Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Stemline Therapeutics (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent No: 1716712.3 pending (I)
Travel, Accommodations, Expenses - Bicycle Therapeutics; Caris Life Sciences; Erasca, Inc; Repare Therapeutics; Sapience Therapeutics; Seagen
 
Marie Robert
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Alejandro Falcon Gonzalez
Consulting or Advisory Role - AstraZeneca; Pfizer; Roche/Genentech; Steve
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Grunenthal; Lilly; Novartis; Pfizer; Roche/Genentech; Seagen
 
Damien Pouessel
Honoraria - AAA/Endocyte/Novartis; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; MSD Oncology; Pfizer/Astellas
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb/Medarex; Eisai; Merck; MSD Oncology; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen Oncology; Pfizer
 
Iosune Baraibar
Honoraria - AstraZeneca
Travel, Accommodations, Expenses - Amgen; Merck; SERVIER
 
Alexander Stein
Consulting or Advisory Role - Amgen (Inst); AstraZeneca; Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); Merck KGaA; MSD (Inst); Novartis (Inst); Pierre Fabre (Inst); Pierre Fabre (Inst); Roche; SERVIER (Inst); Taiho Oncology (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Daiichi Sankyo Europe GmbH (Inst); Merck KGaA; Seagen (Inst); Servier
Research Funding - Bristol-Myers Squibb (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pierre Fabre (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH
 
Haeseong Park
Consulting or Advisory Role - Merck
Research Funding - Amgen (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); D3Bio (Inst); Exelixis (Inst); Huoata Bio (Inst); Idience (Inst); Incyte (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Strata Oncology (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Amgen
 
Matthew Reilley
Consulting or Advisory Role - Pfizer; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Cardiff Oncology (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Surface Oncology (Inst); Takeda (Inst); Xencor (Inst); ZielBio (Inst)
 
Benoit You
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Clovis Oncology; Daiichi Sankyo Europe GmbH; ECS PROGASTRIN; Eisai; GlaxoSmithKline; Immunomedics; LEK; MSD Oncology; Myriad Genetics; Novartis; Pharma&; Roche/Genentech; Seagen; TESARO
Research Funding - Clovis Oncology (Inst); Merck Serono (Inst); NOVARTIS (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BMS; MSD Oncology; Roche/Genentech; SEAGEN
 
Rasha Cosman
No Relationships to Disclose
 
Zhong Wang
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Taylor Jew
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Yijia Wang
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Anwaar Saeed
Consulting or Advisory Role - Arcus therapeutics; Astellas Pharma; AstraZeneca; Autem therapeutics; Bristol-Myers Squibb; Exelixis; Pfizer; Taiho Pharmaceutical; Xilio therapeutics
Research Funding - Actuate Therapeutics (Inst); Arcus therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Incyte (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Oxford biotherapeutics (Inst); Replimune (Inst)